Zy­dus Cadila drug gets USFDA nod

The Hindu Business Line - - FRONT PAGE - PTI

Zy­dus Cadila has re­ceived ap­proval from the US health reg­u­la­tor to market as­pirin and ex­tended re­lease dipyri­damole cap­sules, used to pre­vent ex­ces­sive blood clot­ting and re­duce the risk of strokes. Shares of the com­pany’s listed en­tity Cadila Health­care af­ter the an­nounce­ment rose by over 2 per cent to ₹510 apiece on the BSE. The com­pany has re­ceived fi­nal ap­proval from the US Food and Drug Ad­min­is­tra­tion to market the drug in the strengths of 25mg/200mg, Zy­dus Cadila said in a BSE fil­ing.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.